Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.

Front Oncol 2015 11;5:29. Epub 2015 Feb 11.

Department of Leukemia, MD Anderson Cancer Center , Houston, TX , USA.

Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% (1). Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases (2). Recombinant activated Factor VII [rFVIIa (NovoSeven(®))] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa for the treatment of acute hemorrhage in patients without hemophilia has been successful (3, 4). Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the setting of newly diagnosed AML.

Download full-text PDF

Source
http://journal.frontiersin.org/Article/10.3389/fonc.2015.000
Publisher Site
http://dx.doi.org/10.3389/fonc.2015.00029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324079PMC
February 2015
7 Reads

Publication Analysis

Top Keywords

activated factor
8
factor vii
8
newly diagnosed
8
myeloid leukemia
8
recombinant activated
8
acute myeloid
8
intracranial hemorrhage
8
[rfviia novoseven®]
4
novoseven®] approved
4
vii [rfviia
4
cases recombinant
4
approved treatment
4
treatment bleeding
4
fviii inhibitors
4
complications fviii
4
bleeding complications
4
aml cases
4
complications aml
4
disorders disseminated
4
63% bleeding
4

References

(Supplied by CrossRef)

Similar Publications